WALTHAM, Mass., Oct. 13 -- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013. This growth will be fueled by a growing drug-treated population, improved patient access to healthcare insurance, greater patient spending power and the increased use of biological agents in rheumatoid arthritis treatment. Western companies will continue to earn the largest share of the rheumatoid arthritis market in India.
“During our 2008 to 2013 study period, sales in the rheumatoid arthritis drug market in India will be propelled by the uptake of more expensive drugs including currently available biologics such as Amgen-Wyeth’s Enbrel, Schering-Plough’s Remicade, Abbott’s Humira, Roche’s MabThera and Bristol-Myers-Squibb’s Orencia and the launch of new biological agents such as Roche’s Actemra and Schering-Plough’s Simponi. Although the overall patient share of biological agents amounts to a mere nine percent of the total rheumatoid arthritis population in 2013, their high prices will result in considerable market growth,” stated Manashi Sherawat, Ph.D., analyst at Decision Resources.
The new Emerging Markets report entitled Rheumatoid Arthritis in India also finds that among the three emerging agents launching between 2008 and 2013 in India-Simponi, Actemra and UCB’s Cimzia-Simponi will have the greatest commercial success. Simponi’s once a month dosing and higher efficacy compared with its originator, Remicade, will allow it to tap into the self-pay rheumatoid arthritis patient population. By 2013, Simponi sales are forecasted to account for 12 percent of the total rheumatoid arthritis market share in India.
Webinar
Members of the media are welcome to attend our upcoming webinar entitled India, China and Brazil: Cutting Through the Noise in the Rheumatoid Arthritis Drug Market. This webinar will be held on Wednesday, October 14, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at [email protected].
About Emerging Markets Reports
Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
